App-Quantinova.ai

Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.

Carolyn Marie Larsen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nilotinib

Second primary maligancies in acute promyelocytic leukemia.

Nibash Budhathoki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cytogenetics and survival trends in Hispanic Latino patients with acute lymphoblastic leukemia at Los Angeles County Hospital and Norris Cancer Center.

Golnaz Vahdani - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clearance of circulating leukemic blasts during induction therapy to predict treatment response regardless of cytogenetic risk or age in adult acute myeloid leukemia.

Zhou Yu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cytarabine liposomal

Outpatient induction therapy in newly diagnosed non M3 acute myeloid leukemia.

Ashish Manne - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cytarabine liposomal

Feasibility and safety of cardiopulmonary exercise testing (CPET) in adults newly diagnosed with acute leukemia undergoing induction therapy.

Ashley Leak Bryant - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Isocitrate dehydrogenase (IDH) mutation testing in the clinical management of acute myeloid leukemia (AML) - an international comparison.

Pieter De Richter - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Self-reported quality-of-life (QoL) impairment and productivity loss in patients with polycythemia vera (PV) enrolled in the REVEAL study.

Michael Richard Grunwald - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prognostic factors of advanced Hodgkins lymphoma: multivariate analysis of 199 Chinese patients with long-term follow-up.

Qin Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Roxithromycin

Clinicopathologic features and survival outcomes of secondary diffuse large b-cell lymphoma after a primary solid malignancy: SEER propensity-matched analysis.

Muhammad Saad Hamid - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Incidence and risk factors for ibrutinib associated atrial fibrillation.

Josephine Ngozi Emole - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ibrutinib

Pre-cancer cardiovascular risk factors and anthracycline-related cardiotoxicity among non-Hodgkin lymphoma survivors.

Talya Salz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

NK/T cell lymphoma in the U.S: A population-based study using the National Cancer Database from 1998-2012.

Amritha C. Karkera - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The prognostic impact of serum albumin in double hit/double expressing aggressive B cell lymphomas: A pilot study evaluating SAAB scoring system.

Chetasi Talati - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Development of non-Hodgkin lymphoma as a second primary cancer in patients with chronic hepatitis C virus infection.

Minas P. Economides - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical significance of gastrointestinal involvement in human immunodeficiency virus (HIV) patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Abdul Rafeh Naqash - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adjuvant chemotherapy and radiation options and their associated outcomes in surgically-resected non-small cell carcinoma.

Lisa Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Possible utility of actinin-4 as a predictive biomarker of the efficacy of postoperative adjuvant chemotherapy for completely resected early stage lung adenocarcinoma.

Hideaki Shiraishi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vinorelbine

Phase I study of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small cell lung cancer patients with brain metastases: neurocognitive and quality-of-life analysis.

You Lu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Icotinib

Is there an optimal time to initiate adjuvant chemotherapy in order to predict the benefit of survival in NSCLC?

Xiaoyu Zhai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts